Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiST phase II stratified therapy trial in relapsed malignant mesothelioma
ISRCTN39816629Phase 2Completed
- Sponsor
- University of Leicester
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of rucaparib, abemaciclib, pembrolizumab, bemcentinib, atezolizumab and 3 more in mesothelioma (5 arms), sponsored by University of Leicester. Primary endpoint: Disease control rate at 12 weeks. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
mesothelioma
Beyond the preview
Go deeper on ISRCTN39816629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN39816629.